Vecuronium bromide

Thông tin thuốc gốc
Chỉ định và Liều dùng
Facilitate endotracheal intubation, Facilitate mechanical ventilation in intensive care, Muscle relaxant in general anaesthesia
Adult: Initially, 100 mcg/kg by inj. Maintenance: 20-40 mcg/kg by inj or as continuous infusion at 0.8-1.4 mcg/kg/min. Surgical procedures after intubation with suxamethonium: 40-60 mcg/kg. Surgery under halothane and neuroleptic anaesthesia: Initially, 150-400 mcg/kg.
Child: >7 weeks to <1 year Same with adult but use of high doses is not required and requirement of maintenance dose is less frequent; 2-10 years Same initial and maintenance doses as for adults, but maintenance doses are required more frequently.
Nhóm bệnh nhân đặc biệt
Obese patients (≥130% of ideal body wt): Reduce dose, taking into account an ideal body wt.
Hướng dẫn pha thuốc
Add 10 mL or 20 mL of bacteriostatic water for inj to a vial containing 10 mg or 20 mg of the drug, respectively, to provide a soln containing 1 mg/mL. Further dilute to the desired concentration (usually, 0.1-0.2 mg/mL) to be used for IV infusion.
Tương kỵ
Furosemide, alkaline soln (e.g. thiopental).
Thận trọng
Patient w/ CV disease, oedema, neuromuscular disease, previous poliomyelitis, burn injury, severe electrolyte disturbances, altered blood pH, dehydration; obese patient. Hepatic and renal impairment. Childn. Pregnancy and lactation.
Tác dụng không mong muốn
Skeletal muscle weakness or paralysis, resp insufficiency or apnoea, bronchospasm, hypotension, tachycardia, acute urticaria, erythema, minimal induration, redness, itching, CV effects (e.g. changes in heart rate, cardiac index), myopathy.
Potentially Fatal: Anaphylaxis.
Chỉ số theo dõi
Monitor BP, heart rate; peripheral nerve stimulation.
Quá liều
Symptoms: Skeletal muscle weakness, decreased resp reserve, low tidal vol, apnoea. Management: Maintain a patent airway w/ manual or mechanical ventilation. May administer pyridostigmine, neostigmine or edrophonium in conjunction w/ atropine or glycopyrrolate to antagonise the muscle relaxant effect.
Tương tác
Increased effect w/ halogenated volatile anaesth (e.g. enflurane, isoflurane, halothane), certain antibiotics (e.g. aminoglycosides, lincosamide and polypeptide antibiotics, acylamino-penicillin antibiotics), diuretics, quinidine, Mg and lithium salts, Ca channel blockers, cimetidine, lidocaine and acute admin of phenytoin or β-blockers. Decreased effect w/ phenytoin and carbamazepine (chronic use), Ca and K salts.
Tác dụng
Description: Vecuronium competes w/ acetylcholine for cholinergic receptor sites, binding w/ nicotinic receptor at the motor end-plate, resulting to neuromuscular blockade.
Onset: Good intubation conditions: W/in 2.5-3 min. Max neuromuscular blockade: W/in 3-5 min.
Duration: Under balanced anaesth (time to recovery to 25% of control): 25-40 min; recovery 95% complete, approx 45-65 min after inj of intubating dose.
Distribution: Rapidly distributed into extracellular space. Volume of distribution: 0.3-0.4 L/kg. Plasma protein binding: 60-80%.
Metabolism: Undergoes partial hepatic metabolism via spontaneous deacetylation to form the active metabolite 3-desacetyl vecuronium.
Excretion: Mainly via bile (as unchanged drug and metabolites), some in urine. Plasma elimination half-life: Approx 30-80 min.
Đặc tính

Chemical Structure Image
Vecuronium bromide

Source: National Center for Biotechnology Information. PubChem Database. Vecuronium bromide, CID=39764, (accessed on Jan. 23, 2020)

Bảo quản
Store between 20-25°C. Protect from light.
Phân loại MIMS
Thuốc ức chế thần kinh cơ
Phân loại ATC
M03AC03 - vecuronium ; Belongs to the class of other quaternary ammonium-containing agents used as peripherally-acting muscle relaxants.
Tài liệu tham khảo
Anon. Vecuronium Bromide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 05/08/2015.

Buckingham R (ed). Vecuronium Bromide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 05/08/2015.

McEvoy GK, Snow EK, Miller J et al (eds). Vecuronium Bromide. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 05/08/2015.

Vecuronium Bromide Injection, Lyophilized Powder for Solution (Mylan Institutional LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 05/08/2015.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Vecuronium bromide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2023 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Norcuron
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in